"Mercaptopurine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
| Descriptor ID |
D015122
|
| MeSH Number(s) |
D02.886.489.534 D03.633.100.759.534
|
| Concept/Terms |
Mercaptopurine- Mercaptopurine
- 6-Thiopurine
- 6 Thiopurine
- 6-Mercaptopurine Monohydrate
- 6 Mercaptopurine Monohydrate
- 1,7-Dihydro-6H-purine-6-thione
- 6-Thiohypoxanthine
- 6 Thiohypoxanthine
|
Below are MeSH descriptors whose meaning is more general than "Mercaptopurine".
Below are MeSH descriptors whose meaning is more specific than "Mercaptopurine".
This graph shows the total number of publications written about "Mercaptopurine" by people in this website by year, and whether "Mercaptopurine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mercaptopurine" by people in Profiles.
-
Association between thiopurine exposure and depression in patients with inflammatory bowel disease and rheumatoid arthritis. J Psychopharmacol. 2020 10; 34(10):1163-1167.
-
NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon. Pediatr Blood Cancer. 2017 01; 64(1):146-150.
-
Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group. Pediatr Blood Cancer. 2014 Dec; 61(12):2236-42.
-
Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014 Aug; 24(8):387-96.
-
6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3. Am J Physiol Endocrinol Metab. 2013 Nov 01; 305(9):E1081-92.
-
Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8.
-
Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005 Jan 20; 23(3):541-7.
-
Local immunosuppression of the vascularized graft. Surgery. 1990 Feb; 107(2):209-14.
-
Local immunosuppression with reduced systemic toxicity in a canine renal allograft model. Transplantation. 1989 Dec; 48(6):936-43.